Key Highlights
- Everest’s proprietary AI+mRNA platform drives breakthroughs in personalized and off-the-shelf cancer vaccines, promising to redefine treatment outcomes
- Phase I trials for EVM16 and EVM14, coupled with in vivo CAR-T innovations, strengthen Everest’s dual-engine strategy and internal innovation push
- Strong investor and partner interest positions Everest as a key regional leader in next-generation immunotherapies
Reimagining Cancer Vaccines with AI-Optimized Personalization
At the 2025 Everest Medicines R&D Day, the company showcased EVM16, a personalized cancer vaccine built on its proprietary EVER-NEO-1 AI neoantigen prediction engine. Leveraging third-generation mRNA sequence optimization, EVM16 encodes tumor-specific neoantigens delivered via advanced lipid nanoparticles, stimulating potent, targeted T-cell responses. Preclinical mouse melanoma data showed synergy with PD-1 antibodies, while early clinical trial results indicate promising immunogenicity in advanced cancer patients.
Expanding Off-the-Shelf Immunotherapies for Squamous Cell Cancers
EVM14, Everest’s off-the-shelf mRNA therapeutic vaccine, targets five tumor-associated antigens with broad application potential across squamous cell carcinomas. Preclinical studies showed robust immune memory formation and reduced tumor recurrence. Following IND clearance from the U.S. FDA, Everest is progressing to initiate trials in China, with global Phase I enrollment expected in Q3 2025.
Driving Innovation in in vivo CAR-T Therapies
Everest’s proprietary targeted LNP (tLNP) platform supports its innovative in vivo CAR-T program, enabling off-the-shelf, lymphodepletion-free, and dose-controllable treatment strategies. Preclinical studies in humanized mouse and primate models demonstrated strong T-cell transfection, potent CAR expression, and efficient B-cell clearance, reinforcing its potential as a new class of cell and gene therapies for both cancer and autoimmune disorders.
Transforming Asia’s Biopharma Landscape through Strategic Execution
Everest Medicines is advancing from a licensing-focused business model to an innovation-driven platform, integrating discovery, optimization, and manufacturing under one umbrella. Backed by collaborations with top global pharmaceutical partners, the company aims to expand its reach in oncology, autoimmune disease, infectious disease, and beyond. As Everest strengthens its intellectual property portfolio and scales production capabilities, its AI-powered mRNA platform promises to reshape cancer care and set new standards across the region.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. With deep expertise across discovery, clinical development, regulatory affairs, and commercialization, Everest has built a robust pipeline of potentially first-in-class or best-in-class molecules in key therapeutic areas including renal diseases, infectious diseases, and autoimmune disorders.
By